Back

Association of Y-chromosomal gr/gr deletions with testicular germ cell tumor: whole-genome analysis of 198,306 individuals

Choi, S.; Rocca, M. S.; Vinanzi, C.; Pluta, J.; Kuzbari, Z.; Loveday, C.; Allen, S.; Torr, B.; Weathers, B.; Anson-Cartwright, L.; Feldman, D. R.; Gietema, J. A.; Gonzalez-Neira, A.; Hamilton, R. J.; Krausz, C.; Moirano, G.; Nead, K. T.; Nsengimana, J.; Poynter, J. N.; Vaughn, D. J.; Kanetsky, P. A.; Nathanson, K. L.; Ferlin, A.; Turnbull, C.; Rowlands, C. F.

2026-02-05 oncology
10.64898/2026.02.04.26345360 medRxiv
Show abstract

PurposeGermline deletions affecting the Y-chromosomal gr/gr region were reported in 2005 as associated with susceptibility to testicular germ cell tumor (TGCT), a highly heritable tumor type that is the most common cancer type affecting adult men under the age of 45. Attempts to replicate this association have been equivocal, primarily due to limited power. MethodsHere, we compare and validate two computational approaches to gr/gr deletion calling in high-, low- and ultra-low-coverage whole genome sequencing data, applying these to two datasets from UK Biobank and the TECAC consortium. We generate dataset-specific effect size estimates for the gr/gr deletion-TGCT association using Firths bias-reduced logistic regression across a total of 198,306 men of European-like ancestry (2231 with and 196,075 without TGCT). ResultsUpon random-effects meta-analysis of estimated effect sizes in the two datasets, we found no significant association between gr/gr deletion status and TGCT risk (combined odds ratio=1.24, 95% CI=0.74-2.07, p=0.42), nor upon stratification of seminoma and non-seminoma/mixed histological subtypes. ConclusionOur analysis suggests gr/gr deletion status alone is likely not predictive of TGCT risk in population-scale analyses of European-like individuals; however, the importance of other proposed determinants of gr/gr deletion impact, including Y-haplogroups and semen phenotype, remains unexplored at scale.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
International Journal of Cancer
42 papers in training set
Top 0.1%
10.0%
2
Nature Communications
4913 papers in training set
Top 23%
8.3%
3
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.1%
6.7%
4
The American Journal of Human Genetics
206 papers in training set
Top 0.8%
6.3%
5
JCO Precision Oncology
14 papers in training set
Top 0.1%
6.3%
6
British Journal of Cancer
42 papers in training set
Top 0.2%
6.3%
7
Scientific Reports
3102 papers in training set
Top 28%
4.3%
8
Cancers
200 papers in training set
Top 2%
3.5%
50% of probability mass above
9
Clinical Epigenetics
53 papers in training set
Top 0.3%
3.5%
10
Journal of Medical Genetics
28 papers in training set
Top 0.1%
3.5%
11
BMC Medicine
163 papers in training set
Top 2%
3.2%
12
Clinical Cancer Research
58 papers in training set
Top 0.6%
2.7%
13
The Journal of Clinical Endocrinology & Metabolism
35 papers in training set
Top 0.5%
2.3%
14
PLOS Medicine
98 papers in training set
Top 2%
2.1%
15
Frontiers in Oncology
95 papers in training set
Top 2%
1.9%
16
PLOS ONE
4510 papers in training set
Top 54%
1.7%
17
BMC Bioinformatics
383 papers in training set
Top 5%
1.5%
18
Cell Reports Medicine
140 papers in training set
Top 5%
1.3%
19
Annals of Oncology
13 papers in training set
Top 0.7%
1.2%
20
eLife
5422 papers in training set
Top 54%
0.9%
21
Cancer Medicine
24 papers in training set
Top 1%
0.9%
22
European Journal of Cancer
10 papers in training set
Top 0.4%
0.9%
23
JAMA Network Open
127 papers in training set
Top 4%
0.9%
24
npj Precision Oncology
48 papers in training set
Top 1%
0.9%
25
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.6%
0.8%
26
Neuro-Oncology
30 papers in training set
Top 0.7%
0.8%
27
eClinicalMedicine
55 papers in training set
Top 2%
0.7%
28
BMC Cancer
52 papers in training set
Top 3%
0.7%
29
Human Reproduction
18 papers in training set
Top 0.4%
0.7%
30
Genetics in Medicine
69 papers in training set
Top 1%
0.7%